psoriatic

Dithranol (cignoline) 是蒽醌衍生物，可破坏线粒体功能和结构，用于治疗皮肤病。

SGC-CBP30 是高选择性CBP p300溴结构域的有效抑制剂，对CBP 和p300的Kd 值分别为 21 和 32 nM。它强烈减少 Th17 细胞中 IL-17A 的分泌，具有抗炎作用。

Leflunomide (HWA486) 是嘧啶合成抑制剂，能够抑制二氢乳清酸脱氢酶，具有抗风湿的活性。

12R-LOX-IN-2 是一种 12R-脂氧合酶 (12R-LOX) 的抑制剂。12R-LOX-IN-2 抑制咪喹莫特 (IMQ) 诱导银屑病角质形成细胞过度增殖，并抑制细胞集落形成。12R-LOX-IN-2 还降低 IMQ 诱导细胞中 Ki67 的蛋白水平和 IL-17A 的 mRNA 表达。12R-LOX-IN-2 可用于牛皮癣和其他皮肤相关炎症性疾病的研究。

PDE4-IN-22 (Compound 2e) 为一种PDE4抑制剂，IC50 测定值仅为2.4 nM。该化合物展示出了抗炎效果，并在Imiquimod 诱导的银屑病小鼠模型中显示出强大的治疗潜力，有效抑制银屑病症状。

Apremilast, (+ -)-, is a small molecule inhibitor of phosphodiesterase 4 (PDE4) with oral activity. It is used to treat psoriatic arthritis.

Imiquimod maleate (R 837 maleate) 是一种 toll 样受体7 (TLR7) 激动剂，也是一种免疫反应修饰剂，具有抗病毒和抗肿瘤作用。Imiquimod maleate 可诱导小鼠银屑病样皮肤病变，可用于研究各种皮肤恶性肿瘤。

β-Defensin-2 is a peptide with antimicrobial properties that protects the skin and mucosal membranes of the respiratory, genitourinary, and gastrointestinal tracts.1It inhibits the growth of periodontopathogenic and cariogenic bacteria, includingP. gingivalisandS. salivarius.2β-Defensin-2 (30 μg/ml) stimulates gene expression and production of IL-6, IL-10, CXCL10, CCL2, MIP-3α, and RANTES by keratinocytes.3It also stimulates calcium mobilization, migration, and proliferation of keratinocytes when used at concentrations of 30, 10, and 40 μg/ml, respectively. β-Defensin-2 induces IL-31 production by human peripheral blood-derived mast cellsin vitrowhen used at a concentration of 10 μg/ml and by rat mast cellsin vivofollowing a 500 ng intradermal dose.4Expression of β-defensin-2 is increased in psoriatic skin and chronic wounds.5,6 1.Lehrer, R.I.Primate defensinsNat. Rev. Microbiol.2(9)727-738(2004) 2.Ouhara, K., Komatsuzawa, H., Yamada, S., et al.Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, β-defensins and LL37, produced by human epithelial cellsJ. Antimicrob. Chemother.55(6)888-896(2005) 3.Niyonsaba, F., Ushio, H., Nakano, N., et al.Antimicrobial peptides human β-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokinesJ. Invest. Dermatol.127(3)594-604(2007) 4.Niyonsaba, F., Ushio, H., Hara, M., et al.Antimicrobial peptides human β-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cellsJ. Immunol.184(7)3526-3534(2010) 5.Huh, W.-K., Oono, T., Shirafuji, Y., et al.Dynamic alteration of human β-defensin 2 localization from cytoplasm to intercellular space in psoriatic skinJ. Mol. Med. (Berl.)80(10)678-684(2002) 6.Butmarc, J., Yufit, T., Carson, P., et al.Human β-defensin-2 expression is increased in chronic woundsWound Repair Regen.12(4)439-443(2004)

Halometasone is a synthetic corticosteroid.1,2Formulations containing halometasone have been used in the treatment of psoriasis vulgaris and eczematous dermatoses. 1.de la Brassine, M., Kint, A., Lachapelle, J.M., et al.Halomethasone (C 48.401-Ba) for the topical treatment of common dermatosesJ. Int. Med. Res.12(5)307-309(1984) 2.Zhu, J.-W., Wu, X.-J., Lu, Z.-F., et al.Role of VEGF receptors in normal and psoriatic human keratinocytes: Evidence from irradiation with different UV sourcesPLoS One8(1)e55463(2013)

IL-17 Modulator 1 (disodium) is a potent, orally active compound, known for its high efficacy in modulating IL-17. This compound is extensively utilized for researching various diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis[1].

(±)13-HODE is one of the two racemic monohydroxy fatty acids resulting from the non-enzymatic oxidation of linoleic acid. It is the principle hydroxylated fatty acid in human psoriatic skin scales, with a mean concentration of 17 ng/mg.[1]

LL-37 is a cationic and α-helical antimicrobial peptide expressed in human bone marrow, testis, granulocytes, and gingival epithelium and is upregulated in psoriatic lesions. It inhibits growth of Gram-positive E. coli D21 and Gram-negative B. megatarium in a concentration-dependent manner and LL-37 expression is induced in A549 epithelial cells, alveolar macrophages, neutrophils, and monocyte-derived macrophages following M. tuberculosis infection. LL-37 binds sheep erythrocytes coated with S. minnesota Re-LPS and induces agglutination with a minimal agglutinating concentration (MAC) of 12.1 μg/ml. It is a chemoattractant for, and can induce calcium mobilization in, human monocytes, neutrophils, and T cells that naturally express formyl peptide receptor-like 1 (FPRL1) and FPRL1-transfected HEK293 cells. LL-37 (10-15 μM) pretreatment of dengue virus type 2 (DENV-2) reduces its infectivity as well as levels of viral genomic RNA and NS1 antigen. In vivo, LL-37 inhibits cecal ligation and puncture-induced caspase-1 activation and pyroptosis of peritoneal macrophages, reduces levels of the inflammatory cytokines IL-1β, IL-6, and TNF-α, and improves survival in polybacterial septic mice.

Guselkumab (CNTO 1959) 是一种针对IL-23p19亚基的重组人IgG1单克隆抗体。Guselkumab 与人和食蟹猴IL-23结合，Kd 值分别为3.3和1.9 pmol L。Guselkumab 对IL-23信号通路下游细胞因子的产生具有抑制作用，可用于银屑病关节炎的研究。

IL-17 modulator 1 is an orally active small molecule. It is highly efficacious in modulating IL-17 and can effectively prevent, treat, or ameliorate various diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis.

IRAK4-IN-21 是选择性的、口服具有活力的、强效的 IRAK4 抑制剂，能够作用于 IRAK4 (IC50: 5 nM) 和 TAK1 (IC50: 56 nM)。IRAK4-IN-21 对 IL-23 的产生表现出有效的抑制作用，其 IC50值为0.17 μM。IRAK4-IN-21 能够用于研究自身免疫性疾病，如斑块状银屑病和银屑病关节炎。

IRAK4-IN-22 是选择性的、口服具有活力的、强效的 IRAK4 抑制剂，能够作用于 IRAK4 (IC50: 3 nM) 和 TAK1 (IC50: 17 nM)。IRAK4-IN-21 对 IL-23 的产生表现出有效的抑制作用，其 IC50值为0.10 μM。IRAK4-IN-21 能够用于研究自身免疫性疾病，如斑块状银屑病和银屑病关节炎。

Clazakizumab是一种具有高亲和力和特异性的单克隆抗体，针对IL-6(白细胞介素-6)细胞因子。它可能对抑制COVID-19中因SARS-CoV-2引起的细胞因子反应有帮助。此外，Clazakizumab也被用于研究银屑病关节炎(PsA)和肾抗体介导的排斥反应。

Risankizumab (BI 655066) 是一种人源化靶向 IL-23 p19 亚基的 IgG 单克隆抗体(Kd <10 pM)。 Risankizumab 能抑制人 IL-23 在小鼠脾细胞中诱导的 IL-17 产生，IC50 值为 2 pM。Risankizumab 可用于预防和治疗如寻常型银屑病、银屑病关节炎、广泛性脓疱型银屑病和红皮病型银屑病类的免疫性和炎症性疾病。

Perakizumab (RG4934) 是一种靶向 IL-17A 的人源化单克隆抗体，可用于研究银屑病关节炎等自身免疫性疾病。

Vunakizumab 是一种靶向 IL-17A 的人源化 IgGκ 单克隆抗体，常与白细胞介素 22 链接形成 Vunakizumab-IL22 来研究流感病毒引起的肺免疫损伤。Vunakizumab 可用于研究银屑病关节炎，通过与IL-17A结合发挥作用。

Neihulizumab (ALTB-168) 是一种免疫检查点激动性抗体，可与人 CD162 (PSGL-1)结合，导致活化的 T 细胞下调。Neihulizumab 可用于类固醇难治性急性移植物抗宿主病 (SR-aGVHD)、银屑病、银屑病关节炎和溃疡性结肠炎的研究。

Efalizumab 是一种新型针对 T 细胞的有效调节剂，是人源化 LFA-1 α 亚基（CD11a）单克隆抗体。Efalizumab 对 T 细胞激活、皮肤T细胞运输和T细胞粘附到角质形成细胞有抑制作用，可用于研究斑块银屑病和银屑病关节炎。

Certolizumab pegol (Certolizumab) 是一种聚乙二醇化和人源化抗 TNF-α 单克隆抗体，可用于研究类风湿性关节炎 （RA）、银屑病关节炎 （PsA） 和中轴型脊柱关节炎 （axSpA）等自身免疫疾病。

QL-1200186为具备口服活性与选择性的TYK2抑制剂。经口服后，该药剂量依赖性抑制因interleukin-12刺激所诱导的interferon-γ产生，并在银屑病模型小鼠中显著改善皮肤病变状况。